Prudential Financial Inc. lifted its holdings in Embecta Corp. (NASDAQ:EMBC - Free Report) by 41.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 154,580 shares of the company's stock after purchasing an additional 45,290 shares during the quarter. Prudential Financial Inc. owned 0.27% of Embecta worth $3,192,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Embecta by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 7,025,483 shares of the company's stock worth $145,076,000 after buying an additional 28,031 shares during the last quarter. American Century Companies Inc. increased its position in shares of Embecta by 8.0% in the fourth quarter. American Century Companies Inc. now owns 3,261,934 shares of the company's stock valued at $67,359,000 after acquiring an additional 242,668 shares during the last quarter. Geode Capital Management LLC raised its holdings in Embecta by 3.4% during the third quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company's stock worth $19,564,000 after acquiring an additional 45,228 shares in the last quarter. William Blair Investment Management LLC bought a new position in Embecta in the fourth quarter valued at approximately $15,270,000. Finally, Bank of New York Mellon Corp grew its stake in Embecta by 0.7% in the fourth quarter. Bank of New York Mellon Corp now owns 685,493 shares of the company's stock valued at $14,155,000 after purchasing an additional 4,769 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company's stock.
Insiders Place Their Bets
In other news, Director Milton Mayo Morris sold 3,100 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total value of $50,778.00. Following the completion of the sale, the director now directly owns 36,133 shares of the company's stock, valued at $591,858.54. This trade represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.42% of the company's stock.
Embecta Trading Up 0.7 %
Shares of Embecta stock traded up $0.09 on Monday, reaching $12.09. 931,033 shares of the company were exchanged, compared to its average volume of 448,691. The company has a market capitalization of $702.84 million, a price-to-earnings ratio of 12.09, a PEG ratio of 0.78 and a beta of 1.23. Embecta Corp. has a one year low of $9.93 and a one year high of $21.48. The company has a 50-day moving average of $14.48 and a 200 day moving average of $16.12.
Embecta (NASDAQ:EMBC - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Analysts predict that Embecta Corp. will post 2.85 earnings per share for the current year.
Embecta Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 4.96%. The ex-dividend date of this dividend was Friday, February 28th. Embecta's payout ratio is currently 60.00%.
Embecta Profile
(
Free Report)
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Read More
Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
